About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID
Ghr
growth hormone receptor
MGI:95708
140 phenotypes from 10 alleles in 12 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background
Annotated Term Reference
Ghrm1Btlr/Ghr+
C57BL/6J-Ghrm1Btlr
decreased body weight J:221475
Ghrm1Btlr/Ghrm1Btlr
C57BL/6J-Ghrm1Btlr
decreased body size J:221475
decreased body weight J:221475
Ghrtm1.1Dlr/Ghrtm1.1Dlr
Tg(Ins2-cre)25Mgn/0
involves: 129S4/SvJae * C3H * C57BL/6 * DBA
decreased insulin secretion J:173909
decreased pancreatic beta cell mass J:173909
decreased pancreatic beta cell proliferation J:173909
increased circulating glucose level J:173909
Ghrtm1.1Jero/Ghr+
B6.129X1-Ghrtm1.1Jero
decreased body weight J:155335
Ghrtm1.1Jero/Ghrtm1.1Jero
B6.129X1-Ghrtm1.1Jero
decreased body weight J:155335
decreased circulating insulin-like growth factor I level J:155335
decreased epididymal fat pad weight J:155335
decreased inguinal fat pad weight J:155335
decreased length of long bones J:155335
decreased liver weight J:155335
increased brain weight J:155335
increased circulating growth hormone level J:155335
increased percent body fat/body weight J:155335
Ghrtm1.1Masp/Ghrtm1.1Masp
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJaeSor * C57BL/6 * DBA
decreased bone mineral density J:152627
decreased circulating insulin-like growth factor I level J:152627
decreased circulating triglyceride level J:152627
decreased kidney weight J:152627
decreased liver triglyceride level J:152627
hepatic steatosis J:152627
impaired glucose tolerance J:152627
increased circulating free fatty acid level J:152627
increased circulating growth hormone level J:152627
increased circulating insulin level J:152627
increased liver weight J:152627
Ghrtm1.2Masp/Ghrtm1.2Masp
involves: 129S4/SvJaeSor
decreased body size J:152627
postnatal growth retardation J:152627
Ghrtm1Arge/Ghrtm1Arge
involves: 129S/SvEv * C57BL/6J
abnormal chondrocyte morphology J:66913
abnormal long bone epiphyseal plate proliferative zone J:66913
abnormal long bone hypertrophic chondrocyte zone J:66913
abnormal trabecular bone morphology J:66913
decreased circulating insulin-like growth factor I level J:66913
decreased litter size J:66913
decreased width of hypertrophic chondrocyte zone J:66913
delayed endochondral bone ossification J:66913
delayed sexual maturation J:66913
increased circulating growth hormone level J:66913
postnatal growth retardation J:66913
proportional dwarf J:66913
small kidney J:66913
small spleen J:66913
Ghrtm1c(KOMP)Wtsi/Ghrtm1c(KOMP)Wtsi
Tg(Fabp4-cre)1Rev/0
involves: C57BL/6N
abnormal fluid regulation J:206358
decreased circulating adiponectin level J:206358
decreased spleen weight J:206358
normal homeostasis/metabolism phenotype J:206358
increased body weight J:206358
increased brown adipose tissue amount J:206358
increased circulating insulin-like growth factor I level J:206358
increased circulating interleukin-6 level J:206358
increased circulating leptin level J:206358
increased gonadal fat pad weight J:206358
increased kidney weight J:206358
increased lean body mass J:206358
increased mesenteric fat pad weight J:206358
increased retroperitoneal fat pad weight J:206358
increased soleus weight J:206358
increased subcutaneous adipose tissue amount J:206358
increased total body fat amount J:206358
increased white fat cell size J:206358
Ghrtm1Jjk/Ghr+
involves: 129P2/OlaHsd * BALB/c
decreased body length J:44604
postnatal growth retardation J:44604
Ghrtm1Jjk/Ghrtm1Jjk
involves: 129P2/OlaHsd
decreased body weight J:155335
decreased circulating insulin-like growth factor I level J:155335
decreased epididymal fat pad weight J:95149
decreased liver weight J:95149
increased brain weight J:95149
increased circulating growth hormone level J:155335
postnatal growth retardation J:95149
small kidney J:95149
Ghrtm1Jjk/Ghrtm1Jjk
involves: 129P2/OlaHsd * BALB/c
abnormal artery morphology J:157146
abnormal avoidance learning behavior J:96518
abnormal body weight J:63459
abnormal bone ossification J:60207
abnormal circulating lipid level J:105686
abnormal compact bone morphology J:60207
abnormal epididymis weight J:105921
abnormal food intake J:105686
abnormal learning/memory/conditioning J:96518
abnormal long bone epiphyseal plate morphology J:60207
abnormal metestrus J:79216
abnormal ovarian follicle morphology J:79216
abnormal ovary physiology J:79216
abnormal seminal vesicle weight J:105921
abnormal skeleton development J:60207
abnormal spermatid morphology J:105921
abnormal spermatogenesis J:105921
abnormal testes secretion J:53777, J:105921
decreased areal bone mineral density J:60207
decreased birth weight J:55142
decreased body length J:44604, J:60207, J:105686
decreased body size J:44604, J:63459
decreased body weight J:53777, J:63459, J:105686, J:105921, J:110613, J:132437, J:157146
decreased bone mineral content J:60207, J:105686
decreased brain weight J:132437
decreased circulating cholesterol level J:105686
decreased circulating estradiol level J:79216
decreased circulating glucose level J:105686, J:110613
decreased circulating HDL cholesterol level J:105686
decreased circulating insulin level J:105686, J:110613
decreased circulating insulin-like growth factor I level J:44604, J:53777, J:60207, J:63459
decreased circulating LDL cholesterol level J:105686
decreased circulating luteinizing hormone level J:53777
decreased circulating testosterone level J:53777, J:105921
decreased circulating triglyceride level J:105686
decreased circulating VLDL cholesterol level J:105686
decreased corpora lutea number J:79216
decreased epididymis weight J:105921
decreased fetal size J:55142
decreased fetal weight J:55142
decreased heart weight J:60207, J:157146
decreased kidney weight J:60207, J:132437
decreased lean body mass J:105686
decreased length of long bones J:60207
decreased litter size J:44604, J:55142, J:79216
decreased liver weight J:60207, J:105686, J:132437
decreased ovulation rate J:79216
decreased pituitary gland weight J:53777
decreased prostate gland weight J:53777
decreased seminal vesicle weight J:53777, J:105921
decreased spleen weight J:60207
decreased susceptibility to autoimmune diabetes J:59132
decreased systemic arterial systolic blood pressure J:157146
decreased testis weight J:53777, J:60207, J:105921
decreased triiodothyronine level J:60207
delayed balanopreputial separation J:105921
delayed female fertility J:44604
delayed male fertility J:79216
delayed sexual maturation J:55142, J:79216, J:105921
delayed vaginal opening J:55142
extended life span J:63459
female infertility J:79216
fetal growth retardation J:55142
impaired embryo implantation J:79216
impaired luteinization J:79216
impaired ovarian folliculogenesis J:79216
increased brain weight J:60207, J:105686
increased circulating adiponectin level J:132437
increased circulating corticosterone level J:105686
increased circulating growth hormone level J:44604
increased circulating leptin level J:105686
increased circulating prolactin level J:53777
increased food intake J:105686
increased insulin sensitivity J:110613
increased interscapular fat pad weight J:105686
increased percent body fat/body weight J:105686, J:132437
increased placenta weight J:55142
increased retroperitoneal fat pad weight J:105686, J:132437
increased uterus weight J:55142
increased white adipose tissue amount J:132437
long gestation period J:55142
obese J:105686
perinatal lethality, incomplete penetrance J:44604, J:55142
postnatal growth retardation J:44604, J:63459
postnatal lethality, incomplete penetrance J:44604
prolonged diestrus J:79216
prolonged estrous cycle J:79216
proportional dwarf J:44604
reduced male fertility J:53777
short femur J:60207
short tibia J:60207
Ghrtm1Jjk/Ghrtm1Jjk
involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6
decreased activity of thyroid gland J:103286
decreased body temperature J:103286
decreased circulating glucose level J:103286
decreased circulating insulin level J:103286
decreased circulating thyroxine level J:103286
decreased circulating triiodothyronine level J:103286
increased circulating corticosterone level J:103286
Ghrtm1Jjk/Ghrtm1Jjk
involves: 129P2/OlaHsd * BALB/c * C57BL/6
abnormal blood homeostasis J:107763
decreased body weight J:107763
decreased circulating glucagon level J:107763
decreased circulating glucose level J:107763
decreased circulating insulin level J:107763
decreased circulating insulin-like growth factor I level J:107763
decreased liver weight J:107763
decreased pancreatic beta cell mass J:107763
hypoglycemia J:107763
increased abdominal fat pad weight J:107763
increased circulating chloride level J:107763
increased circulating creatine kinase level J:107763
increased circulating serum albumin level J:107763
increased insulin sensitivity J:107763
postnatal growth retardation J:107763
small pancreatic islets J:107763
Ghrtm1Mwat/Ghr+
involves: 129X1/SvJ * C57BL
postnatal growth retardation J:95149
Ghrtm1Mwat/Ghrtm1Mwat
involves: 129X1/SvJ * C57BL
decreased circulating insulin-like growth factor I level J:95149
hyperglycemia J:95149
increased brain weight J:95149
postnatal growth retardation J:95149
Ghrtm2Mwat/Ghr+
involves: 129X1/SvJ * C57BL
postnatal growth retardation J:95149
Ghrtm2Mwat/Ghrtm2Mwat
involves: 129X1/SvJ * C57BL
decreased circulating insulin-like growth factor I level J:95149
decreased liver weight J:95149
hyperglycemia J:95149
increased brain weight J:95149
increased total body fat amount J:95149
postnatal growth retardation J:95149
small kidney J:95149
small spleen J:95149

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
08/13/2019
MGI 6.14
The Jackson Laboratory